[25] MET amplification may predict sensitivity to MET inhibitors such as crizotinib, a dual Alk/Met inhibitor that is approved by the Food and Drug Administration for the treatment of patients with ALK-positive non–small cell lung cancer. The gene discussed is ALK; the disease is lung cancer.